首页> 美国卫生研究院文献>British Journal of Pharmacology and Chemotherapy >Inhibition of nitric oxide synthesis by NG-nitro-L-arginine methyl ester (L-NAME): requirement for bioactivation to the free acid NG-nitro-L-arginine.
【2h】

Inhibition of nitric oxide synthesis by NG-nitro-L-arginine methyl ester (L-NAME): requirement for bioactivation to the free acid NG-nitro-L-arginine.

机译:NG-硝基-L-精氨酸甲酯(L-NAME)抑制一氧化氮的合成:对游离酸NG-硝基-L-精氨酸进行生物活化的要求。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

1. The L-arginine derivatives NG-nitro-L-arginine (L-NOARG) and NG-nitro-L-arginine methyl ester (L-NAME) have been widely used to inhibit constitutive NO synthase (NOS) in different biological systems. This work was carried out to investigate whether L-NAME is a direct inhibitor of NOS or requires preceding hydrolytic bioactivation to L-NOARG for inhibition of the enzyme. 2. A bolus of L-NAME and L-NOARG (0.25 micromol) increased coronary perfusion pressure of rat isolated hearts to the same extent (21 +/- 0.8 mmHg; n = 5), but the effect developed more rapidly following addition of L-NOARG than L-NAME (mean half-time: 0.7 vs 4.2 min). The time-dependent onset of the inhibitory effect of L-NAME was paralleled by the appearance of L-NOARG in the coronary effluent. 3. Freshly dissolved L-NAME was a 50 fold less potent inhibitor of purified brain NOS (mean IC50 = 70 microM) than L-NOARG (IC50 = 1.4 microM), but the apparent inhibitory potency of L-NAME approached that of L-NOARG upon prolonged incubation at neutral or alkaline pH. H.p.l.c. analyses revealed that NOS inhibition by L-NAME closely correlated with hydrolysis of the drug to L-NOARG. 4. Freshly dissolved L-NAME contained 2% of L-NOARG and was hydrolyzed with a half-life of 365 +/- 11.2 min in buffer (pH 7.4), 207 +/- 1.7 min in human plasma, and 29 +/- 2.2 min in whole blood (n = 3 in each case). When L-NAME was preincubated in plasma or buffer, inhibition of NOS was proportional to formation of L-NOARG, but in blood the inhibition was much less than expected from the rates of L-NAME hydrolysis. This was explained by accumulation of L-NOARG in blood cells. 5. These results suggest that L-NAME represents a prodrug lacking NOS inhibitory activity unless it is hydrolyzed to L-NOARG. Bioactivation of L-NAME proceeds at moderate rates in physiological buffers, but is markedly accelerated in tissues such as blood or vascular endothelium.
机译:1. L-精氨酸衍生物NG-硝基-L-精氨酸(L-NOARG)和NG-硝基-L-精氨酸甲酯(L-NAME)在不同的生物系统中已广泛用于抑制本构NO合酶(NOS)。 。进行这项工作以研究L-NAME是NOS的直接抑制剂还是需要事先水解生物活化为L-NOARG来抑制酶。 2.大剂量L-NAME和L-NOARG(0.25微摩尔)可使大鼠离体心脏的冠状动脉灌注压力增加相同的程度(21 +/- 0.8 mmHg; n = 5),但在添加L-NAME和L-NOARG的情况下,其作用更快L-NOARG比L-NAME(平均半场时间:0.7对4.2分钟)。 L-NAME抑制作用的时间依赖性发作与冠状流出物中L-NOARG的出现平行。 3.新鲜溶解的L-NAME对纯化脑NOS的抑制作用(平均IC50 = 70 microM)比L-NOARG(IC50 = 1.4 microM)低50倍,但L-NAME的表观抑制力接近L-NOARG(IC50 = 1.4 microM)。在中性或碱性pH下长时间孵育后会产生NOARG。 H.p.l.c.分析表明,L-NAME对NOS的抑制作用与药物水解为L-NOARG密切相关。 4.新鲜溶解的L-NAME含有2%的L-NOARG,在缓冲液(pH 7.4)中的半衰期为365 +/- 11.2分钟,在人血浆中的半衰期为207 +/- 1.7分钟,在29 + / -全血2.2分钟(每种情况下n = 3)。当在血浆或缓冲液中预孵育L-NAME时,NOS抑制与L-NOARG的形成成比例,但是在血液中,抑制作用远小于L-NAME水解速率所预期的。 L-NOARG在血细胞中的积累解释了这一点。 5.这些结果表明,除非将其水解为L-NOARG,否则L-NAME代表缺乏NOS抑制活性的前药。 L-NAME的生物活化在生理缓冲液中以中等速度进行,但在血液或血管内皮等组织中明显加速。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号